Ivo Abraham, PhD, RN, University of Arizona Cancer Center, urges stakeholders to provide patient advocacy groups with comprehensive information about specific drugs and drug classes to increase ...

Patients with rheumatoid arthritis who switched from the etanercept originator to a biosimilar exhibited similar disease ...

Researchers surveyed clinicians from 63 countries and found that adalimumab and infliximab biosimilars, primarily chosen for their lower cost, are widely available and have improved access to biologic ...

A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole ...

On this episode of Not So Different, the end of the second quarter brings with it expense reports, new biosimilar business ...

With the end of the second quarter comes expense reports, new biosimilar business deals, and insights into how federal policy ...

Market remonopolization by a biosimilar drug in Poland led to significant price increases for etanercept, resulting in over ...

Jeffrey Casberg discusses key upcoming biosimilars and specialty drugs, the impact of the Inflation Reduction Act on drug pricing, and the evolving role of pharmacy benefit managers in the market.

European Alliance of Associations for Rheumatology (EULAR) recommendations for psoriatic arthritis (PsA) provide an evidence-based treatment strategy, prioritizing conventional and biological ...

Number 5: With the end of the second quarter comes expense reports, new biosimilar business deals, and insights into how federal policy impacts biosimilar company pursuits. Number 4: The 2023 European ...